MetaVia's DA-1726 significantly reduces uric acid levels in Phase 1 trial
MTVA•MetaVia reported that DA-1726 significantly reduced uric acid versus placebo in adults with obesity in Phase 1 Part 3B. The company expects full Part 3A and 3B data in the first quarter of 2027 and plans to start a 48-week Phase 2 trial in the second half of 2027.
1. Phase 1 findings
MetaVia reported additional Phase 1 Part 3B results showing that DA-1726 significantly reduced uric acid in adults with obesity versus placebo. Previously reported interim findings showed reduced liver fat, weight loss and improved blood sugar control; all treated participants who had liver steatosis at baseline achieved normal liver fat levels.
2. Next studies
MetaVia expects full Phase 1 Part 3A and Part 3B data in the first quarter of 2027. It plans a 48-week Phase 2 trial targeting up to 150 participants with MetALD and ALD, starting in the second half of 2027.
